Filippos Triposkiadis, Andrew Xanthopoulos, Stavros G Drakos, Konstantinos Dean Boudoulas, Alexandros Briasoulis, John Skoularigis, Konstantinos Tsioufis, Harisios Boudoulas, Randall C Starling
The left ventricular (LV) ejection fraction (LVEF), despite its severe limitations, has had an epicentral role in heart failure (HF) classification, management, and risk stratification for decades. The major argument favoring the LVEF based HF classification has been that it defines groups of patients in which treatment is effective. However, this reasoning has recently collapsed, since medical treatment with neurohormonal inhibitors, has proved beneficial in most HF patients regardless of the LVEF. In addition, there has been compelling evidence, that the LVEF provides poor guidance for device treatment of chronic HF (implantation of cardioverter defibrillator, cardiac resynchronization therapy) since sudden cardiac death may occur and cardiac dyssynchronization may be disastrous in all HF patients...
February 10, 2024: Current Problems in Cardiology